1.	Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC12153, 2011-001897-25, U1111-1121-7170, NCT01437787
2.	Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARD12042, 2011-001847-58, U1111-1121-4203, NCT01420783
3.	Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARD12181, 2011-005226-21, U1111-1124-0967, NCT01523171
4.	Drug Interaction Study of SAR302503 in Patients With Solid Tumor Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: INT12497, U1111-1125-8930, NCT01585623